Celia Lin, MD
Assistant Clinical Professor
Medicine
School of Medicine

Education & Training

Show all (5) Hide

• Internal Medicine Residency Boston Medical Center
• BS General Chemistry with Business and Administration Specialization UCLA
• Rheumatology Fellowship UCLA
• MD University of Rochester School of Medicine
• Rheumatology Fellowship and Post-doc Washington University in St. Louis

Publications (31)

Top publication keywords:
ApoferritinsMembrane Cofactor ProteinReceptors, TransferrinViral Matrix ProteinsVariola virusAntibodies, Monoclonal, HumanizedLung Diseases, InterstitialBone Density Conservation AgentsHemolytic-Uremic SyndromeScleroderma, SystemicComplement ActivationDenosumabComplement Activating EnzymesRecombinant Fusion ProteinsComplement C3

• A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
  Kidney international 2024 Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, Jha V, Kim SG, Maes B, Phoon RK, Singh H, Tesar V, Lin CJ, Barratt J
• Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
  Rheumatology (Oxford, England) 2024 Ghuman A, Khanna D, Lin CJF, Furst DE, Raghu G, Martinez FJ, Zucchetto M, Huang S, Jennings A, Nihtyanova SI, Denton CP
• Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis.
  Clinical immunology (Orlando, Fla.) 2023 Sheng XR, Gao X, Schiffman C, Jiang J, Ramalingam TR, Lin CJF, Khanna D, Neighbors M
• Atacicept-it's not over until the wolf-lady sings (or maybe howls).
  Rheumatology (Oxford, England) 2023 Isenberg DA, Lin CJF
• Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
  American journal of respiratory and critical care medicine 2022 Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, Martinez FJ, Goldin J, Siegel J, Denton CP

Show all (26 more) Hide

• Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
  Critical care medicine 2022 Tom J, Bao M, Tsai L, Qamra A, Summers D, Carrasco-Triguero M, McBride J, Rosenberger CM, Lin CJF, Stubbings W, Blyth KG, Carratalà J, François B, Benfield T, Haslem D, Bonfanti P, van der Leest CH, …
• Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial.
  Open forum infectious diseases 2021 Kumar PN, Hernández-Sánchez J, Nagel S, Feng Y, Cai F, Rabin J, Morse CG, Nadig NR, Ashraf O, Gotur DB, McComsey GA, Gafoor K, Perin P, Thornton SC, Stubbings W, Lin CJF, Tsai L
• Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
  Arthritis & rheumatology (Hoboken, N.J.) 2021 Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, Huang S, Khanna D, focuSSced Investigators
• New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
  Annals of the rheumatic diseases 2020 Khanna D, Huang S, Lin CJF, Spino C
• Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
  The Lancet. Respiratory medicine 2020 Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP, focuSSced investigators
• Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population.
  Rheumatology and therapy 2019 Gale SL, Trinh H, Mathew N, Jahreis A, Lin CJF, Sarsour K
• Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2019 Bilezikian JP, Lin CJF, Brown JP, Wang AT, Yin X, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C, Chines A
• Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment.
  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2019 Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwinski E, de Greg?rio LH, Malouf-Sierra J, Reginster JY, Wang A, Wagman RB, Lewiecki EM
• Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez.
  Annals of the rheumatic diseases 2018 Khanna D, Jahreis A, Lin CJF
• Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting.
  The Journal of rheumatology 2017 Lau AN, Wong-Pack M, Rodjanapiches R, Ioannidis G, Wade S, Spangler L, Balasubramanian A, Pannacciulli N, Lin CJF, Roy-Gayos P, Bensen WG, Bensen R, Adachi JD
• Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
  Annals of the rheumatic diseases 2017 Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L,…
• Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.
  BMC musculoskeletal disorders 2017 Adachi JD, Bone HG, Daizadeh NS, Dakin P, Papapoulos S, Hadji P, Recknor C, Bolognese MA, Wang A, Lin CJF, Wagman RB, Ferrari S
• Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.
  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2016 Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O'Malley CD, Saag K, Curtis JR
• The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2015 Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwinski E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati …
• Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis.
  Nature immunology 2011 Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S, Barrera J, Huang EJ, Hou B, Malynn BA, Reizis B, DeFranco A, Criswell LA, Nakamura MC, Ma A
• Binding and uptake of H-ferritin are mediated by human transferrin receptor-1.
  Proceedings of the National Academy of Sciences of the United States of America 2010 Li L, Fang CJ, Ryan JC, Niemi EC, Lebrón JA, Björkman PJ, Arase H, Torti FM, Torti SV, Nakamura MC, Seaman WE
• Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.
  Journal of immunology (Baltimore, Md. : 1950) 2009 Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP
• Inhibiting complement activation on cells at the step of C3 cleavage.
  Vaccine 2008 Liszewski MK, Fang CJ, Atkinson JP
• Advances in understanding of pathogenesis of aHUS and HELLP.
  British journal of haematology 2008 Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP
• Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.
  Blood 2007 Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP
• Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
  Molecular immunology 2006 Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship TH, Atkinson JP
• Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.
  Blood 2006 Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP,…
• Manipulation of immune regulation in systemic lupus erythematosus.
  Autoimmunity reviews 2005 La Cava A, Fang CJ, Singh RP, Ebling F, Hahn BH
• The rationale for renewed interest by physicians in nutrition.
  Current atherosclerosis reports 1999 Pearson TA, Bloch R, Dorantes J, Gordian A, Fang C, Swanson J, Brown K
• The effects of graded hypoxia on intraparenchymal arterioles in rat brain slices.
  Neuroreport 1998 Staunton M, Dulitz MG, Fang C, Schmeling WT, Kampine JP, Farber NE
• Conformation of T4 lysozyme in solution. Hinge-bending motion and the substrate-induced conformational transition studied by site-directed spin labeling.
  Biochemistry 1997 Mchaourab HS, Oh KJ, Fang CJ, Hubbell WL